Open Payments

Valley Childrens Hospital

Type
Teaching hospital
Where
Madera, CA
Medicare CCN
053300
Received
$130,986 in 44 records, 2022 ($6,467 general, $124,519 research)
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2022General payment19$6,467
2022Research payment25$124,519

By company

CompanyRecordsAmountYears
VERTEX PHARMACEUTICALS INCORPORATED1$58,0322022
PFIZER INC.2$24,8002022
Novartis Gene Therapies, Inc. (fka Avexis, Inc.)8$17,7892022
Gilead Sciences, Inc.2$16,6252022
Incyte Corporation12$7,2732022
Smith+Nephew, Inc.1$3,9012022
JAZZ PHARMACEUTICALS INC.1$1,5002022
Medical Graphics Corporation1$5592022
Cochlear Americas1$1942022
KARL STORZ Endoscopy-America13$1612022
Merge Healthcare Incorporated2$1502022

By nature of payment

NatureRecordsAmount
Research payment25$124,519
Debt forgiveness14$4,062
Space rental or facility fees (teaching hospital only)1$1,500
Gift1$559
Long term medical supply or device loan1$194
Food and Beverage2$150

Records

DateCompanyAmountNatureFormProductStudyYear
2022-12-19KARL STORZ Endoscopy-America$2Debt forgivenessIn-kind items and services2022
2022-12-14Novartis Gene Therapies, Inc. (fka Avexis, Inc.)$1,613Research paymentCash or cash equivalentA PROSPECTIVE, LONG-TERM REGISTRY OF PATIENTS WITH A DIAGNOSIS OF SPINAL MUSCULAR ATROPHY2022
2022-12-07KARL STORZ Endoscopy-America$12Debt forgivenessIn-kind items and services2022
2022-12-04Smith+Nephew, Inc.$3,901Debt forgivenessCash or cash equivalentPeri-Loc Device, Trauma Plates, Screws, and Nails2022
2022-11-19JAZZ PHARMACEUTICALS INC.$1,500Space rental or facility fees (teaching hospital only)Cash or cash equivalentEPIDIOLEX Drug, NEUROLOGY2022
2022-11-16Novartis Gene Therapies, Inc. (fka Avexis, Inc.)$50Research paymentCash or cash equivalentA PROSPECTIVE, LONG-TERM REGISTRY OF PATIENTS WITH A DIAGNOSIS OF SPINAL MUSCULAR ATROPHY2022
2022-10-25Merge Healthcare Incorporated$70Food and BeverageCash or cash equivalentSoftware Device, Medical Imaging2022
2022-10-24KARL STORZ Endoscopy-America$31Debt forgivenessIn-kind items and services2022
2022-09-28Novartis Gene Therapies, Inc. (fka Avexis, Inc.)$50Research paymentCash or cash equivalentA PROSPECTIVE, LONG-TERM REGISTRY OF PATIENTS WITH A DIAGNOSIS OF SPINAL MUSCULAR ATROPHY2022
2022-08-24KARL STORZ Endoscopy-America$6Debt forgivenessIn-kind items and services2022
2022-08-15KARL STORZ Endoscopy-America$2Debt forgivenessIn-kind items and services2022
2022-08-03Novartis Gene Therapies, Inc. (fka Avexis, Inc.)$50Research paymentCash or cash equivalentA PROSPECTIVE, LONG-TERM REGISTRY OF PATIENTS WITH A DIAGNOSIS OF SPINAL MUSCULAR ATROPHY2022
2022-07-20PFIZER INC.$6,200Research paymentCash or cash equivalentA RANDOMIZED OPEN LABEL ACTIVE CONTROLLED SAFETY AND DESCRIPTIVE EFFICACY STUDY IN PEDIATRIC SUBJECTS REQUIRING ANTICOAG2022
2022-07-13PFIZER INC.$18,600Research paymentCash or cash equivalentA RANDOMIZED OPEN LABEL ACTIVE CONTROLLED SAFETY AND DESCRIPTIVE EFFICACY STUDY IN PEDIATRIC SUBJECTS REQUIRING ANTICOAG2022
2022-07-07Novartis Gene Therapies, Inc. (fka Avexis, Inc.)$3,310Research paymentCash or cash equivalentA PROSPECTIVE, LONG-TERM REGISTRY OF PATIENTS WITH A DIAGNOSIS OF SPINAL MUSCULAR ATROPHY2022
2022-07-06KARL STORZ Endoscopy-America$9Debt forgivenessIn-kind items and services2022
2022-06-30KARL STORZ Endoscopy-America$12Debt forgivenessIn-kind items and services2022
2022-06-28Medical Graphics Corporation$559Gift (2 payments)In-kind items and services2022
2022-06-01KARL STORZ Endoscopy-America$8Debt forgivenessIn-kind items and services2022
2022-06-01KARL STORZ Endoscopy-America$8Debt forgivenessIn-kind items and services2022
2022-05-27KARL STORZ Endoscopy-America$0Debt forgivenessIn-kind items and services2022
2022-05-23Gilead Sciences, Inc.$8,925Research paymentCash or cash equivalentVeklury Drug, COVID-19A Phase 2/3 Single-Arm, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Remdesi2022
2022-05-13KARL STORZ Endoscopy-America$39Debt forgivenessIn-kind items and services2022
2022-05-11Novartis Gene Therapies, Inc. (fka Avexis, Inc.)$3,226Research paymentCash or cash equivalentA PROSPECTIVE, LONG-TERM REGISTRY OF PATIENTS WITH A DIAGNOSIS OF SPINAL MUSCULAR ATROPHY2022
2022-05-04Incyte Corporation$5,000Research paymentCash or cash equivalentA Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr2022
2022-05-04Incyte Corporation$2,000Research paymentCash or cash equivalentA Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr2022
2022-05-02Merge Healthcare Incorporated$80Food and BeverageCash or cash equivalentSoftware Device, Medical Imaging2022
2022-04-12Cochlear Americas$194Long term medical supply or device loanIn-kind items and servicesCochlear Device, Implantable hearing solution2022
2022-04-04Gilead Sciences, Inc.$7,700Research paymentCash or cash equivalentVeklury Drug, COVID-19A Phase 2/3 Single-Arm, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Remdesi2022
2022-03-30Novartis Gene Therapies, Inc. (fka Avexis, Inc.)$5,024Research paymentCash or cash equivalentA PROSPECTIVE, LONG-TERM REGISTRY OF PATIENTS WITH A DIAGNOSIS OF SPINAL MUSCULAR ATROPHY2022
2022-02-08Incyte Corporation$69Research paymentCash or cash equivalentA Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr2022
2022-02-08Incyte Corporation$42Research paymentCash or cash equivalentA Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr2022
2022-02-08Incyte Corporation$40Research paymentCash or cash equivalentA Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr2022
2022-02-08Incyte Corporation$37Research paymentCash or cash equivalentA Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr2022
2022-02-08Incyte Corporation$32Research paymentCash or cash equivalentA Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr2022
2022-02-08Incyte Corporation$24Research paymentCash or cash equivalentA Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr2022
2022-02-08Incyte Corporation$12Research paymentCash or cash equivalentA Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr2022
2022-02-08Incyte Corporation$12Research paymentCash or cash equivalentA Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr2022
2022-02-08Incyte Corporation$0Research paymentCash or cash equivalentA Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr2022
2022-02-08Incyte Corporation$0Research paymentCash or cash equivalentA Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr2022
2022-01-28VERTEX PHARMACEUTICALS INCORPORATED$58,032Research paymentCash or cash equivalentA Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy2022
2022-01-26Novartis Gene Therapies, Inc. (fka Avexis, Inc.)$4,464Research paymentCash or cash equivalentA PROSPECTIVE, LONG-TERM REGISTRY OF PATIENTS WITH A DIAGNOSIS OF SPINAL MUSCULAR ATROPHY2022
2022-01-21KARL STORZ Endoscopy-America$19Debt forgivenessIn-kind items and services2022
2022-01-16KARL STORZ Endoscopy-America$7Debt forgivenessIn-kind items and services2022

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

Madera CountyMadera city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Madera, CA, county Madera County, CA, state California; placed by its city name.

MeasurePlace (city or town)
Madera, CA
County
Madera County, CA
State
California
Population B0100367,831160,94039,287,377
Population, 2020 census P166,224156,25539,538,223
Median age B0100230.434.637.9
Under 18 B0100130.8%27.1%22.0%
65 and over B010019.6%14.4%15.7%
Households B1100117,52645,37913,548,091
Foreign born B0500225.6%20.1%27.0%
Median household income B19013$63,933$76,627$99,122
Median family income B19113$67,479$83,389$113,346
Per capita income B19301$24,200$30,077$49,513
Poverty rate B1700125.6%19.2%12.0%
Unemployment rate B2302512.6%10.1%6.6%
Civilian labor force B2302529,99769,01220,068,466
Mean commute (minutes) B0801325.727.928.7
Bachelor's degree or higher B1500310.9%17.9%37.1%
Housing units B2500118,56251,01514,644,735
Owner-occupied B2500354.7%67.5%55.9%
Renters B2500345.3%32.5%44.1%
Median home value B25077$359,900$393,200$734,700
Median gross rent B25064$1,353$1,390$2,036
White, not Hispanic B0300212.2%29.9%33.8%
Black B030022.9%2.4%5.2%
Hispanic or Latino B0300281.1%60.9%40.2%
Asian B030021.3%2.4%15.3%
American Indian and Alaska Native B030020.1%0.4%0.3%

Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); Unemployment rate: 5.5% in Sep 2016 to 5.1% in Sep 2026; low 3.8%, high 16.1% the state; Source: FRED, Federal Reserve Bank of St. Louis.

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Madera, CA.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.